Ensysce Biosciences

Closed (deSPAC)

Profile in progress

What it is: Biosciences Ensysce Biosciences San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs
What it’s doing now: Merging with Leisure Acquisition Corp. (LACQ) — closed (despac).
What you should know: Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Biosciences Ensysce Biosciences San Diego, CA is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com .

What the company says about itself

Web research — not audited

Ensysce Biosciences is a biotech company committed to stemming the prescription drug abuse epidemic. They utilize innovative chemistry platforms, including TAAP™ for preventing drug abuse and MPAR® for preventing drug overdose, applied to oral prescription drugs. The company has received FDA 'Fast Track' and 'Breakthrough Therapy' designations.

Markets:: Biotechnology | Pain Therapeutics | Drug Abuse Prevention
Products:: TAAP™ | MPAR® | PF614-MPAR-102

Source: https://ensysce.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Ensysce Biosciences is merging with Leisure Acquisition Corp. (LACQ) currently marked Closed (deSPAC).

Headline equity value	—
PIPE	≈ $63M · unsourced

Structure per SEC accession(s) 0001493152-21-005991. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Ensysce Biosciences going public?

Ensysce Biosciences has an approved merger with the SPAC Leisure Acquisition Corp. (LACQ). Deal status: Closed (deSPAC).

Does Ensysce Biosciences have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.